Kamaljit Kaur

Dr. Kamaljit Kaur

Associate Professor
Pharmacy, School of Pharmacy
Expertise: Antimicrobial Peptides; Pathogenic Bacteria; Breast Cancer; Cancer-Targeting Agents; Cancer Diagnostics
Office Location: 9401 297X
Education:
University of Delhi, Bachelor of Science
Indian Institute of Technology, Master of Science
Case Western Reserve University, Ph.D.

Biography

Dr. Kamaljit Kaur is an Associate Professor in the Department of Biomedical and Pharmaceutical Sciences and serves as Director of the Center for Targeted Drug Delivery. She received her Ph.D. in Bioorganic Chemistry from Case Western Reserve University, completed her postdoctoral training at Wesleyan University and at the University of Alberta, and subsequently joined the University of Alberta as an Assistant Professor of Medicinal Chemistry in the Faculty of Pharmacy and Pharmaceutical Sciences.In 2014, she joined Chapman University as a Distinguished Chancellor Fellow and became a full-time tenured Associate Professor and a founding member of the School of Pharmacy.

 Dr. Kaur has supervised 70+ students and hasmentoredseveral postdoctoral fellows and junior faculty.She has published 75+ peer-reviewed articles, authored four book chapters, and holds3+ approved patents. She has delivered 35+invited talks nationally and internationally.She serves on review panelsfor major funding agencies, including the National Institutes of Health and the Canadian Institutes of Health Research. She is aneditorial board member of Scientific Reports and Pharmaceutics and has served on the Long Range Planning Committee of the American Chemical Society Division of Medicinal Chemistry.

Research Interests

Dr. Kaur’sresearchfocuses onmedicinal chemistry, with an emphasis onpeptide engineering for the development of therapeutics and diagnostics. Her group has made significant contributions to targeted drug delivery using engineered peptides and peptide-based platforms for biosensor development.

Projects in her laboratory include:

 Peptide-drug conjugates (PDCs) to enhance the efficacy and safety of chemotherapy for triple-negative breast cancer and melanoma
Brain-targeted conjugates for the treatment of Alzheimer’s disease
Antimicrobial Peptidesto combat pathogenic Gram-positive and Gram-negative multi-drug resistant bacteria

Recent Creative, Scholarly Work and Publications

Jack Jhamandas, Rania Soudy, Kamaljit Kaur, When Fu, David, Mactavish, Aarti Patel, Brain Penetrant Amylin Receptor Based Peptides for Alzheimer’s Disease, U.S. Patent Application No. 62/396,370 filed May 2017.